Contribute Try STAT+ Today

Elizabeth Holmes may be guilty in the minds of millions who consumed the best-selling book, the dueling documentaries, and the chart-topping podcasts about the downfall of Theranos. But, when it comes to her fate, the only opinions that matter are those of the 12 jurors who will spend the next three months deciding whether Holmes is the ringleader of massive fraud or just a Silicon Valley dreamer who tilted over her skis.

And despite overwhelming public opinion, convincing them to convict won’t be easy, legal experts said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment